There is renewed interest and enthusiasm for the potential pathophysiological role of inflammation and immune dysfunction in patients with schizophrenia, with evidence for abnormalities in the blood, CSF, and CNS.
Psychosis is one of the key dimensions of schizophrenia, bipolar disorder, and psychotic depression. Clinicians are familiar with patients whose psychosis improves dramatically with antipsychotic treatment; however, these patients may be left with cognitive impairment, negative mood symptoms, or suicidal symptoms, as well as impaired work and social functioning.
Catatonia—a syndrome of disturbed motor, mood, and systemic signs (eg, rigidity, immobility, mutism, staring, posturing, waxy flexibility, echopraxia, echolalia, and stereotypies)—has led to the clarification of its appropriate treatment.
"Psychosis Risk" can now be diagnosed as “Attenuated Psychosis Syndrome” and used to bill for insurance reimbursement. Many bearing the diagnostic label are young adolescents and adults in whom schizophrenia or any other psychotic disorder will never develop.
What effect has the new antipsychotic Latuda had in patients with psychosis? Is a mood stabilizer as an adjunctive therapy necessary for schizophrenia or is the use of an antipsychotic alone sufficient?
There has been substantial interest lately on the early stages of schizophrenia and the effects of untreated psychosis. Clinical trials have focused on medications for first episode, assessments of adverse effects, and “care paths” for the early/prodromal stage of psychosis.